LianBio’s mission is to catalyze development and accelerate availability of paradigm‑shifting medicines to patients in China and major Asian markets through partnerships that provide access to science‑driven therapeutic discoveries. The company says it collaborates with world‑class partners across a diverse array of therapeutic and geographic areas to build a pipeline based on disease relevance and the ability to impact patients with transformative mechanisms and precision‑based therapeutics. LianBio describes a global innovation mining platform and says the platform has been validated by a syndicate of institutional investors. The company is building commercial and development capabilities to advance partnered programs in China and other major Asian markets. Management cited the success and momentum of the company’s recent launch and said the new financing will provide additional support for those efforts. LianBio is referenced from Shanghai and Princeton, N.J., and emphasizes addressing significant unmet medical needs in the region.

Total raised

$310M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2020